

UTILITY PATENT APPLICATION TRANSMITTAL <i>(Only for new nonprovisional applications under 37 CFR 1.53(b))</i>	Attorney Docket No.	M0656/7065
	First Named Inventor or Application Identifier	
	Krause et al.	
	Express Mail Label No.	EL711251919US
Date of Deposit		April 3, 2001

APPLICATION ELEMENTS <i>See MPEP chapter 600 concerning utility patent application contents</i>	ADDRESS TO: Box Patent Application Commissioner for Patents Washington, DC 20231
1. <input type="checkbox"/> Fee Transmittal Form <i>(Submit an original, and a duplicate for fee processing)</i> 2. <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. <input type="checkbox"/> Statement filed in prior application, status still proper and desired. 3. <input checked="" type="checkbox"/> Specification -Total pages 63 54 - pages description 1 - page abstract 8 - pages claims 72 - Total claims 4. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) 3 - Total sheets <input checked="" type="checkbox"/> Informal <input type="checkbox"/> Formal 3 - Total drawings 5. <input type="checkbox"/> Oath or Declaration - Total pages a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 18 completed)</i> [Note Box 6 below] i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 6. <input type="checkbox"/> Incorporation by Reference <i>(usable if Box 5b is checked)</i> The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. See 18. 7. <input type="checkbox"/> Application Data Sheet, See 37 CFR 1.76	8. <input type="checkbox"/> CD-ROM or CD-R, in duplicate, large table or Computer Program (Appendix) 9. <input checked="" type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input checked="" type="checkbox"/> Computer Readable Form (CRF) b. <input checked="" type="checkbox"/> Specification Sequence Listing on: i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. <input checked="" type="checkbox"/> paper copy (identical to computer copy) c. <input checked="" type="checkbox"/> Statement verifying identity of above ACCOMPANYING APPLICATION PARTS 10. <input type="checkbox"/> Assignment Papers/cover sheet & documents(s) 11. <input type="checkbox"/> 37 CFR 3.73(b) Statement <i>(when there is an assignee)</i> <input type="checkbox"/> Power of Attorney 12. <input type="checkbox"/> English Translation of Document <i>(if applicable)</i> 13. <input type="checkbox"/> Information Disclosure Statement/PTO-1449 <input type="checkbox"/> Copies of IDS Citations 14. <input type="checkbox"/> Preliminary Amendment 15. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i> 16. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i> 17. <input type="checkbox"/> Other: e.g., Verified Statement of Small Entity Status; Request and Certification Under 35 U.S.C. §122(b)(2)(B)(ii) _____ _____ _____

18. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in the body of the application, or a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____, filed on _____, entitled _____ and now _____.

Prior application information: Examiner _____ Group Art Unit: _____

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

Correspondence address below

CUSTOMER NUMBER:



23628

OR

20. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME	John R. Van Amsterdam, Reg. No. 40,212
SIGNATURE	
DATE	April 3, 2001

Attorney's Docket No. M0656/7065 (JRV)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Krause et al.
Serial No. : Unknown
Filed : Herewith
For : METHODS FOR ALTERING T-CELL AND MACROPHAGE
ACTIVATION


Box Patent Application
Commissioner for Patents
Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. §1.821(f)

Sir:

This statement is made pursuant to 37 CFR 1.821(f). Applicants enclose herewith an original written copy of the Sequence Listing and a computer readable diskette. Applicants' attorney states that the information recorded in the computer readable form is identical to the written Sequence Listing and that the Sequence Listing contains no new matter.

Respectfully submitted,


John R. Van Amsterdam, Reg No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210
Tel.: 617-720-3500

Attorney's Docket No.: M0656/7065
Date: April 3, 2001
xNDD